Robert McDowell
Nessuna posizione attualmente
Profilo
Robert Scott McDowell ricopre la posizione di responsabile scientifico di MyoKardia, Inc. In precedenza è stato vicepresidente della ricerca alla Sagimet Biosciences, Inc., scienziato senior alla Genentech, Inc., vicepresidente della ricerca alla Sunesis Pharmaceuticals, Inc. e direttore della chimica strutturale alla Axys Pharmaceuticals, Inc. Si è laureato alla Butler University e ha conseguito un dottorato alla University of California, Berkeley.
Precedenti posizioni note di Robert McDowell
Società | Posizione | Fine |
---|---|---|
MYOKARDIA, INC. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
SAGIMET BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 01/07/2012 |
VIRACTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 04/08/2008 |
Axys Pharmaceuticals, Inc.
Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/2000 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01/01/1999 |
Formazione di Robert McDowell
Butler University | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
SAGIMET BIOSCIENCES INC. | Health Technology |
Aziende private | 4 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Axys Pharmaceuticals, Inc.
Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Robert McDowell